Navigation Links
KineMed Licenses GeneGo's MetaCore
Date:6/10/2008

ST. JOSEPH, Mich., June 10 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that KineMed, Inc. has licensed MetaCore for application to its ongoing multi-center Phase II prognostic study of chronic lymphocytic leukemia (CLL). KineMed's kinetic biomarker of CLL flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease.

"KineMed's biological pathway insights and GeneGo's database for systems biology link network complexity to physiologic phenotypes and disease genotypes which is one of the primary goals for personalized medicine. These insights will answer the challenge of determining the right medicine for the right patient at the right time," said Gregory Hayes, Ph.D., Director of Oncology Research at KineMed. GeneGo's genetic pathway database aligns with KineMed's phenotypic pathway analysis and facilitates identification of genetic polymorphisms and expression patterns that directly link genetics with KineMed's in vivo disease biomarker.

"Building cancer specific pathway analysis software and databases is a key focus area for GeneGo this year," said Julie Bryant, VP business development. "We have a lot of expertise in this area that is reflected in our grants and publications in Science and Cancer cell."

About KineMarker(TM) Technology

KineMed, Inc. is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to identify active drug candidates and rapidly demonstrate human proof-of-concept in selected therapeutic areas. KineMed's KineMarker(TM) technology is designed to quickly demonstrate, preclinically and clinically, whether compounds are "on mechanism" or are acting upon specific physiologic pathways that are the basis for particular diseases. KineMed's technology measures the kinetics of these pathways using a stable isotope labeling technique and mass isotopomer distribution analysis (MIDA), allowing observation of on-target or off-target pathologic or therapeutic changes in patients. The Company also has multiple development programs with major pharmaceutical companies, including Bayer, Merck, Organon and Roche.

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com.

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
2. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
3. NuVasive Licenses Its Insert and Rotate Technology
4. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
5. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Cyberonics Licenses Obesity-Related Patents
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The leader in ... that Drs. Sam Daher , Manal Ibrahim ... and David Couchat will be the featured microlecture presenters ... upcoming American Association of Orthodontists (AAO) Annual Session, April ... attend the microlectures beginning daily at 11:20 a.m. On ...
(Date:3/29/2017)... Texas , March 29, 2017  Maxor National ... today announced that it has named Leah Bailey ... for all divisions of the company. With ... including the previous 8 years focused on health care, ... During her tenure at Prime, Bailey advised the PBM, ...
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
Breaking Medicine Technology: